RADNOR, Pa.--(BUSINESS WIRE)--
Marinus Pharmaceuticals, Inc.
(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 10:20 a.m. ET.
A link to the event can be accessed on the Investors and Media page of Marinus’ website at
ir.marinuspharma.com/events-and-presentations
. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 90 days.
About Marinus Pharmaceuticals
Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company’s product, ZTALMY
®
(ganaxolone) oral suspension CV, is an FDA-approved prescription medication introduced in the U.S. in 2022. For more information, please visit
www.marinuspharma.com
and follow us on
Facebook,
LinkedIn
and
X
.
Source: Marinus Pharmaceuticals